Lwin Zarnie, Leighl Natasha
University of Toronto, Princess Margaret Hospital, Division of Medical Oncology and Haematology, 5-105, 610 University Avenue, Toronto, Ontario M5G 2M9, Canada, USA.
Expert Opin Pharmacother. 2009 Feb;10(2):283-90. doi: 10.1517/14656560802653206.
Breast cancer is among the leading causes of cancer morbidity worldwide and accounts for a significant proportion of overall healthcare costs. Cost-effectiveness and cost-utility evaluations of therapy provide insight into the societal value of different treatments, helping decision-makers to prioritize resource allocation and maximize benefit in cancer control within resource constraints. Docetaxel, a plant alkaloid of the taxane group, has been recognized as a highly active chemotherapy agent in breast, lung and prostate cancers, among others. In the last decade, docetaxel has become incorporated into the neoadjuvant, adjuvant and metastatic treatment of breast cancer. This article reviews the economic data supporting the use of docetaxel in the treatment of breast cancer.
乳腺癌是全球癌症发病的主要原因之一，在总体医疗费用中占相当大的比例。治疗的成本效益和成本效用评估有助于深入了解不同治疗方法的社会价值，帮助决策者在资源有限的情况下优先进行资源分配，并在癌症控制中实现效益最大化。多西他赛是一种紫杉烷类植物生物碱，已被公认为是治疗乳腺癌、肺癌和前列腺癌等多种癌症的高效化疗药物。在过去十年中，多西他赛已被纳入乳腺癌的新辅助、辅助和转移性治疗。本文综述了支持多西他赛用于治疗乳腺癌的经济数据。
